Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$84.12 – $104.61
0% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $794.3M | $833.5M | $845.1M | $1.10B | $1.23B | $1.27B | $1.29B | $1.33B |
| Cost of revenue | $637.8M | $660.8M | $668.9M | $862.9M | $910.6M | $951.1M | $965.5M | $975.9M |
| Gross profit | $156.5M | $172.7M | $176.2M | $239.6M | $318.9M | $320.4M | $329.1M | $352.6M |
| Gross margin | 19.7% | 20.7% | 20.9% | 21.7% | 25.9% | 25.2% | 25.4% | 26.5% |
| R&D | $27.5M | $33.3M | $31.2M | $40.7M | $43.2M | $44.5M | $41.1M | $46.2M |
| Operating income | $76.3M | $57.0M | $79.4M | $132.0M | $230.8M | $172.1M | $199.3M | $210.4M |
| EBITDA | $123.4M | $106.1M | $132.0M | $213.2M | $308.1M | $241.0M | $289.5M | $306.8M |
| Net income | $56.3M | $53.1M | $60.9M | $95.6M | $156.5M | $112.8M | $160.1M | $168.7M |
| Net margin | 7.1% | 6.4% | 7.2% | 8.7% | 12.7% | 8.9% | 12.4% | 12.7% |
| EPS (diluted) | 13.10 | 12.53 | 14.18 | 2.20 | 3.63 | 2.62 | 3.69 | 3.85 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.4B | $3.96 | $3.86–$4.09 | 1 |
| 2027 | $1.5B | $4.55 | $4.44–$4.70 | 1 |
| 2028 | $1.6B | $5.13 | $5.01–$5.30 | 1 |
| 2029 | $1.7B | $5.59 | $5.45–$5.77 | 1 |
Forward consensus · source: Financial Modeling Prep
SIEGFRIED HLDGS LTD NEW
No one on the platform currently holds SGFEF.
No tracked institution reports a position in SGFEF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-04-28 | $0.4000 | 2026-04-30 |
| 2025-04-22 | $3.8000 | 2025-04-24 |
| Execution date | Ratio |
|---|---|
| 2025-04-29 | 10-for-1 |
No one on the platform has traded SGFEF yet.
| $4.3B |
| — |
| HKMPYHikma Pharmaceuticals PLC | $41.23 | +0.00% | $4.4B | — |
| HLUBFH. Lundbeck A/S | $5.50 | +0.00% | $5.8B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.